Recent News
- Radius Health Completes Business Adjustment
Completion
- Radius Announces Update on TYMLOS® (abaloparatide) Label
FDA
- Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
Trial
- Radius Health to Host Conference Call Today, Wednesday, December 8, 2021
BOSTON
- Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis
The
- Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference
BOSTON
- Radius Health, Inc.: Third Quarter 2021 Results
TYMLOS
- Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021
BOSTON
- Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021
BOSTON
- Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
ATOM